Evidence map›Paper›PMID 32221957›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2020

In Vivo Bioluminescence Imaging to Assess Compound Efficacy Against Trypanosoma brucei.

Ryan Ritchie, Michael P Barrett, Jeremy C Mottram, Elmarie Myburgh

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Ryan RitchieWellcome Centre for Integrative Parasitology, Institute of Infection, Immunity & Inflammation, College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, UK.
Michael P BarrettWellcome Centre for Integrative Parasitology, Institute of Infection, Immunity & Inflammation, College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, UK.
Jeremy C MottramYork Biomedical Research Institute, Department of Biology, University of York, York, UK.
Elmarie MyburghYork Biomedical Research Institute, Hull York Medical School, University of York, York, UK. elmarie.myburgh@york.ac.uk.
University of York · GBWellcome Centre for Molecular Parasitology · GB

Funding

Wellcome Trust 104111Wellcome Trust 104976
6 · The paper itself

Abstract

Traditional animal models for human African trypanosomiasis rely on detecting Trypanosoma brucei brucei parasitemia in the blood. Testing the efficacy of new compounds in these models is cumbersome because it may take several months after treatment before surviving parasites become detectable in the blood. To expedite compound screening, we have used a Trypanosoma brucei brucei GVR35 strain expressing red-shifted firefly luciferase to monitor parasite distribution in infected mice through noninvasive whole-body bioluminescence imaging. This protocol describes the infection and in vivo bioluminescence imaging of mice to assess compound efficacy against T. brucei during the two characteristic stages of disease, the hemolymphatic phase (stage 1) and the encephalitic or central nervous system phase (stage 2).

Indexed as

AnimalsDisease Models, AnimalFemaleGenes, ReporterHumansLuciferases, FireflyLuminescent AgentsLuminescent MeasurementsMiceOptical ImagingParasitic Sensitivity TestsTrypanocidal AgentsTrypanosoma brucei bruceiTrypanosomiasis, AfricanLuciferases, FireflyLuminescent AgentsTrypanocidal AgentsBioluminescenceFirefly luciferaseIn vivo imagingTrypanosoma brucei brucei

Identifiers

PMID32221957
PMCPMC9703276
OpenAlexW3012989903

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.